Presented by Dr Joe X Zhou, CEO at Genor Biopharma, Walvax Bio Group
Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several
big blockbusters, Herceptin, Avastin are now among the next biosimilar
targets. This is creating huge potential for biosimilars, prompting
innovators to shift their focus to target more emerging markets which
remain untapped for many companies. In this presentation, Joe will be
sharing with you his vision of the biosimilars market with a focus on
China. He will also discuss key considerations for mAb and biologics
therapeutic development, providing a broad overview of challenges and
opportunities presenting in the market. 1. Landscape
changes of mAb therapeutics 2. New targets and
process/manufacturing innovation 3. Key consideration of
mAb industry in China 4. Case study: Development strategies
of PD-1 mAb as anti-tumor therapeutics in China for global market
Followed by Biosimilar development—how to deal with the similarity
challenge Presented by Sarah (Xuyu) Wang, Head of Segment Marketing,
Biosimilars and Bioconjugations at Sartorius Stedim Biotech Globally
we have more than 1000 biosimilars in the pipeline till the beginning
of 2019, Sales of mAb biosimilars is also taking up as popular targets
being approved both in Europe and US. With the 3rd wave of the
biosimilar coming the challenges is still ahead---how to keep the
similarity from the beginning of the development to the manufacturing
stage and cover the whole lifecycle? With the evolving cell line
development platform, good analytical strategy and QbD implementation
better similarity will be achieved step by step.
food
1156
Views
11/02/2020 Last update